Martin Pettersson currently serves as the Vice President of Drug Discovery at Promedigen, where he is at the forefront of pioneering innovative approaches to drug development. With a robust background in medicinal chemistry and over 20 years of industrial experience, Martin has established himself as...
Martin Pettersson currently serves as the Vice President of Drug Discovery at Promedigen, where he is at the forefront of pioneering innovative approaches to drug development. With a robust background in medicinal chemistry and over 20 years of industrial experience, Martin has established himself as a leader in the field, particularly known for his co-invention of Paxlovid, a groundbreaking antiviral protease inhibitor that has made significant strides in the fight against COVID-19. His expertise lies in leveraging cutting-edge protein engineering technology to create a novel drug discovery platform that targets phosphorylation-dependent protein-protein interactions, a critical area in oncology research.
At Promedigen, Martin is passionately committed to building multidisciplinary teams that tackle complex scientific challenges. His leadership has been instrumental in advancing first-in-class transcription factor targets, which hold promise for transformative therapies in cancer treatment. By enhancing the drug discovery and medicinal chemistry capabilities within the organization, he has successfully generated in vivo proof-of-concept data that underscores the potential of these innovative approaches.
Martin’s skill set encompasses a wide range of disciplines, including organic synthesis, drug design, and clinical development, making him a versatile asset in the life sciences arena. His dedication to improving human health through drug discovery is not only evident in his professional accomplishments but also in his collaborative approach to fostering innovation and excellence in the teams he leads. As he continues to push the boundaries of what is possible in drug development, Martin Pettersson remains a pivotal figure in the ongoing quest to address unmet medical needs.
